{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:04:23Z","timestamp":1793127863636,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81130046"],"award-info":[{"award-number":["81130046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81171993"],"award-info":[{"award-number":["81171993"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272415"],"award-info":[{"award-number":["81272415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Key Project","award":["2013GXNSFEA053004"],"award-info":[{"award-number":["2013GXNSFEA053004"]}]},{"name":"Guangxi Projects","award":["1355004-5"],"award-info":[{"award-number":["1355004-5"]}]},{"name":"Guangxi Projects","award":["2012GXNSFCB053004"],"award-info":[{"award-number":["2012GXNSFCB053004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin J Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40880-017-0184-9","type":"journal-article","created":{"date-parts":[[2017,1,26]],"date-time":"2017-01-26T08:24:34Z","timestamp":1485419074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Metformin targets multiple signaling pathways in cancer"],"prefix":"10.1186","volume":"36","author":[{"given":"Yong","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan T.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Nan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,26]]},"reference":[{"key":"184_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1741-7015-9-33","volume":"9","author":"RJ Dowling","year":"2011","unstructured":"Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.","journal-title":"BMC Med"},{"issue":"3","key":"184_CR2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1210\/endo.131.3.1505458","volume":"131","author":"HS Hundal","year":"1992","unstructured":"Hundal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in l6 muscle cells. Endocrinology. 1992;131(3):1165\u201373.","journal-title":"Endocrinology"},{"issue":"2","key":"184_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/147323001103900203","volume":"39","author":"X Li","year":"2011","unstructured":"Li X, Zhang N, Li Y, et al. Effects of metformin and rosiglitazone on peripheral insulin resistance and beta-cell function in obesity: a double-blind, randomized, controlled study. J Int Med Res. 2011;39(2):358\u201365.","journal-title":"J Int Med Res"},{"issue":"8","key":"184_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1172\/JCI14178","volume":"108","author":"LA Witters","year":"2001","unstructured":"Witters LA. The blooming of the french lilac. J Clin Invest. 2001;108(8):1105\u20137.","journal-title":"J Clin Invest"},{"issue":"5","key":"184_CR5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","volume":"9","author":"IB Sahra","year":"2010","unstructured":"Sahra IB, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9(5):1092\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"184_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1158\/1078-0432.CCR-09-1805","volume":"16","author":"AM Gonzalez-Angulo","year":"2010","unstructured":"Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695\u2013700.","journal-title":"Clin Cancer Res"},{"key":"184_CR7","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1038\/cddis.2011.86","volume":"2","author":"T Tomic","year":"2011","unstructured":"Tomic T, Botton T, Cerezo M, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2:e199.","journal-title":"Cell Death Dis"},{"issue":"2","key":"184_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1096\/fj.11-192088","volume":"26","author":"B Salani","year":"2012","unstructured":"Salani B, Maffioli S, Hamoudane M, et al. Caveolin-1 is essential for metformin inhibitory effect on igf1 action in non-small-cell lung cancer cells. FASEB J. 2012;26(2):788\u201398.","journal-title":"FASEB J"},{"issue":"8","key":"184_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1158\/1940-6207.CAPR-13-0058-T","volume":"6","author":"BJ Quinn","year":"2013","unstructured":"Quinn BJ, Dallos M, Kitagawa H, et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma igf-i and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013;6(8):801\u201310.","journal-title":"Cancer Prev Res (Phila)"},{"key":"184_CR10","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1038\/cddis.2014.59","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng Y, Ke C, Tang Q, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating stat3 signaling. Cell Death Dis. 2014;5:e1088.","journal-title":"Cell Death Dis"},{"issue":"4","key":"184_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/pcan.2012.16","volume":"15","author":"AJ Colquhoun","year":"2012","unstructured":"Colquhoun AJ, Venier NA, Vandersluis AD, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012;15(4):346\u201352.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"184_CR12","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","volume":"20","author":"L Li","year":"2014","unstructured":"Li L, Han R, Xiao H, et al. Metformin sensitizes egfr-tki-resistant human lung cancer cells in vitro and in vivo through inhibition of il-6 signaling and emt reversal. Clin Cancer Res. 2014;20(10):2714\u201326.","journal-title":"Clin Cancer Res"},{"key":"184_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ncomms1859","volume":"3","author":"G Blandino","year":"2012","unstructured":"Blandino G, Valerio M, Cioce M, et al. Metformin elicits anticancer effects through the sequential modulation of dicer and c-myc. Nat Commun. 2012;3:865.","journal-title":"Nat Commun"},{"issue":"5","key":"184_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1159\/000354517","volume":"32","author":"Y Xu","year":"2013","unstructured":"Xu Y, Lu S. Metformin inhibits esophagus cancer proliferation through upregulation of usp7. Cell Physiol Biochem. 2013;32(5):1178\u201386.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"184_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1677\/ERC-09-0252","volume":"17","author":"C Algire","year":"2010","unstructured":"Algire C, Amrein L, Zakikhani M, et al. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010;17(2):351\u201360.","journal-title":"Endocr Relat Cancer"},{"key":"184_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1479-5876-9-76","volume":"9","author":"F Niehr","year":"2011","unstructured":"Niehr F, von Euw E, Attar N, et al. Combination therapy with vemurafenib (plx4032\/rg7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011;9:76.","journal-title":"J Transl Med"},{"key":"184_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/15384047.2014.987021","volume":"16","author":"G Han","year":"2015","unstructured":"Han G, Gong H, Wang Y, et al. Ampk\/mtor-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 2015;16:77\u201387.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"184_CR18","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1002\/ijc.29305","volume":"136","author":"D Zhao","year":"2015","unstructured":"Zhao D, Long XD, Lu TF, et al. Metformin decreases il-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):2556\u201365.","journal-title":"Int J Cancer"},{"issue":"2","key":"184_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.canlet.2014.09.050","volume":"356","author":"FM Zi","year":"2014","unstructured":"Zi FM, He JS, Li Y, et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 2014;356(2):443\u201353.","journal-title":"Cancer Lett"},{"issue":"1\u20132","key":"184_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-013-1845-x","volume":"386","author":"C Qu","year":"2014","unstructured":"Qu C, Zhang W, Zheng G, et al. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (emt) via activating amp-activated protein kinase (ampk) in human breast cancer cells. Mol Cell Biochem. 2014;386(1\u20132):63\u201371.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"184_CR21","doi-asserted-by":"publisher","first-page":"479-e1","DOI":"10.1016\/j.ajog.2014.10.026","volume":"212","author":"E Lengyel","year":"2015","unstructured":"Lengyel E, Litchfield LM, Mitra AK, et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015;212(4):479.e1\u201310. doi:\n                    10.1016\/j.ajog.2014.10.026\n                    \n                  .","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"184_CR22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3892\/or.2014.3611","volume":"33","author":"T Uehara","year":"2015","unstructured":"Uehara T, Mitsuhashi A, Tsuruoka N, et al. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncol Rep. 2015;33(2):744\u201350.","journal-title":"Oncol Rep"},{"issue":"1","key":"184_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1667\/RR13568.1","volume":"182","author":"A Fasih","year":"2014","unstructured":"Fasih A, Elbaz HA, Huttemann M, et al. Radiosensitization of pancreatic cancer cells by metformin through the ampk pathway. Radiat Res. 2014;182(1):50\u20139.","journal-title":"Radiat Res"},{"issue":"24","key":"184_CR24","doi-asserted-by":"publisher","first-page":"12936","DOI":"10.18632\/oncotarget.2683","volume":"5","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Storr SJ, Johnson K, et al. Involvement of metformin and ampk in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget. 2014;5(24):12936\u201349.","journal-title":"Oncotarget"},{"issue":"1","key":"184_CR25","doi-asserted-by":"publisher","first-page":"e84369","DOI":"10.1371\/journal.pone.0084369","volume":"9","author":"P Nangia-Makker","year":"2014","unstructured":"Nangia-Makker P, Yu Y, Vasudevan A, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS ONE. 2014;9(1):e84369.","journal-title":"PLoS ONE"},{"issue":"2","key":"184_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/1871520611313020018","volume":"13","author":"G Barriere","year":"2013","unstructured":"Barriere G, Tartary M, Rigaud M. Metformin: a rising star to fight the epithelial mesenchymal transition in oncology. Anticancer Agents Med Chem. 2013;13(2):333\u201340.","journal-title":"Anticancer Agents Med Chem"},{"issue":"5754","key":"184_CR27","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","volume":"310","author":"RJ Shaw","year":"2005","unstructured":"Shaw RJ, Lamia KA, Vasquez D, et al. The kinase lkb1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642\u20136.","journal-title":"Science"},{"issue":"10","key":"184_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrm2249","volume":"8","author":"DG Hardie","year":"2007","unstructured":"Hardie DG. Amp-activated\/snf1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"184_CR29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cc.8.5.7787","volume":"8","author":"A Vazquez-Martin","year":"2009","unstructured":"Vazquez-Martin A, Lopez-Bonet E, Oliveras-Ferraros C, et al. Mitotic kinase dynamics of the active form of ampk (phospho-ampkalphathr172) in human cancer cells. Cell Cycle. 2009;8(5):788\u201391.","journal-title":"Cell Cycle"},{"issue":"24","key":"184_CR30","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1182\/blood-2011-01-332783","volume":"118","author":"E Vakana","year":"2011","unstructured":"Vakana E, Altman JK, Glaser H, et al. Antileukemic effects of ampk activators on bcr-abl-expressing cells. Blood. 2011;118(24):6399\u2013402.","journal-title":"Blood"},{"issue":"10","key":"184_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/onc.2010.483","volume":"30","author":"C Algire","year":"2011","unstructured":"Algire C, Amrein L, Bazile M, et al. Diet and tumor lkb1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;30(10):1174\u201382.","journal-title":"Oncogene"},{"issue":"1","key":"184_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/leu.2011.269","volume":"26","author":"C Grimaldi","year":"2012","unstructured":"Grimaldi C, Chiarini F, Tabellini G, et al. Amp-dependent kinase\/mammalian target of rapamycin complex 1 signaling in t-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 2012;26(1):91\u2013100.","journal-title":"Leukemia"},{"issue":"3","key":"184_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1055-9965.EPI-08-0871","volume":"18","author":"M Cazzaniga","year":"2009","unstructured":"Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, et al. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009;18(3):701\u20135.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"16","key":"184_CR34","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1158\/0008-5472.CAN-09-0418","volume":"69","author":"K Kisfalvi","year":"2009","unstructured":"Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between g protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009;69(16):6539\u201345.","journal-title":"Cancer Res"},{"issue":"3","key":"184_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/ERC-12-0046","volume":"19","author":"J Klubo-Gwiezdzinska","year":"2012","unstructured":"Klubo-Gwiezdzinska J, Jensen K, Costello J, et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012;19(3):447\u201356.","journal-title":"Endocr Relat Cancer"},{"key":"184_CR36","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1038\/cddis.2012.13","volume":"3","author":"WY Shi","year":"2012","unstructured":"Shi WY, Xiao D, Wang L, et al. Therapeutic metformin\/ampk activation blocked lymphoma cell growth via inhibition of mtor pathway and induction of autophagy. Cell Death Dis. 2012;3:e275.","journal-title":"Cell Death Dis"},{"issue":"5","key":"184_CR37","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1476-5381.2010.01101.x","volume":"162","author":"HG Kim","year":"2011","unstructured":"Kim HG, Hien TT, Han EH, et al. Metformin inhibits p-glycoprotein expression via the nf-kappab pathway and cre transcriptional activity through ampk activation. Br J Pharmacol. 2011;162(5):1096\u2013108.","journal-title":"Br J Pharmacol"},{"issue":"25","key":"184_CR38","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","volume":"27","author":"IB Sahra","year":"2008","unstructured":"Sahra IB, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin d1 level. Oncogene. 2008;27(25):3576\u201386.","journal-title":"Oncogene"},{"issue":"13","key":"184_CR39","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","volume":"71","author":"IB Sahra","year":"2011","unstructured":"Sahra IB, Regazzetti C, Robert G, et al. Metformin, independent of ampk, induces mtor inhibition and cell-cycle arrest through redd1. Cancer Res. 2011;71(13):4366\u201372.","journal-title":"Cancer Res"},{"issue":"3","key":"184_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","volume":"121","author":"A Yasmeen","year":"2011","unstructured":"Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the bcl-2 family proteins. Gynecol Oncol. 2011;121(3):492\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"184_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.radonc.2013.06.014","volume":"108","author":"H Muaddi","year":"2013","unstructured":"Muaddi H, Chowdhury S, Vellanki R, et al. Contributions of ampk and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol. 2013;108(3):446\u201350.","journal-title":"Radiother Oncol"},{"issue":"1","key":"184_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1124\/jpet.109.164970","volume":"334","author":"M Arai","year":"2010","unstructured":"Arai M, Uchiba M, Komura H, et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther. 2010;334(1):206\u201313.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"184_CR43","doi-asserted-by":"publisher","first-page":"e63969","DOI":"10.1371\/journal.pone.0063969","volume":"8","author":"S Gou","year":"2013","unstructured":"Gou S, Cui P, Li X, et al. Low concentrations of metformin selectively inhibit cd133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE. 2013;8(5):e63969.","journal-title":"PLoS ONE"},{"issue":"1","key":"184_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. Mtor: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"184_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00109-011-0726-6","volume":"89","author":"JL Yecies","year":"2011","unstructured":"Yecies JL, Manning BD. Mtor links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 2011;89(3):221\u20138.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"184_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5732\/cjc.014.10289","volume":"34","author":"B Cheaib","year":"2015","unstructured":"Cheaib B, Auguste A, Leary A. The pi3\u00a0k\/akt\/mtor pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34(1):4\u201316.","journal-title":"Chin J Cancer"},{"issue":"8","key":"184_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5732\/cjc.013.10086","volume":"32","author":"W Zhou","year":"2013","unstructured":"Zhou W, Marcus AI, Vertino PM. Dysregulation of mtor activity through lkb1 inactivation. Chin J Cancer. 2013;32(8):427\u201333.","journal-title":"Chin J Cancer"},{"issue":"16","key":"184_CR48","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mtor. Genes Dev. 2004;18(16):1926\u201345.","journal-title":"Genes Dev"},{"issue":"4","key":"184_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J. Mtor signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7(4):209\u201319.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"184_CR50","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1634\/theoncologist.2010-0196","volume":"15","author":"HJ Klumpen","year":"2010","unstructured":"Klumpen HJ, Beijnen JH, Gurney H, et al. Inhibitors of mtor. Oncologist. 2010;15(12):1262\u20139.","journal-title":"Oncologist"},{"issue":"Suppl3","key":"184_CR51","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.3816\/CBC.2010.s.015","volume":"10","author":"R Nahta","year":"2010","unstructured":"Nahta R, O\u2019Regan RM. Evolving strategies for overcoming resistance to her2-directed therapy: targeting the pi3k\/akt\/mtor pathway. Clin Breast Cancer. 2010;10(Suppl3):S72\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"Suppl 3","key":"184_CR52","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3816\/CBC.2010.s.016","volume":"10","author":"A Sheri","year":"2010","unstructured":"Sheri A, Martin LA, Johnston S. Targeting endocrine resistance: is there a role for mtor inhibition? Clin Breast Cancer. 2010;10(Suppl 3):S79\u201385.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"184_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. Tor signaling in growth and metabolism. Cell. 2006;124(3):471\u201384.","journal-title":"Cell"},{"issue":"1","key":"184_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1494","volume":"37","author":"K Inoki","year":"2005","unstructured":"Inoki K, Corradetti MN, Guan KL. Dysregulation of the tsc-mtor pathway in human disease. Nat Genet. 2005;37(1):19\u201324.","journal-title":"Nat Genet"},{"issue":"7092","key":"184_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC. Ras, pi(3)k and mtor signalling controls tumour cell growth. Nature. 2006;441(7092):424\u201330.","journal-title":"Nature"},{"issue":"4","key":"184_CR56","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","volume":"123","author":"MK Holz","year":"2005","unstructured":"Holz MK, Ballif BA, Gygi SP, et al. Mtor and s6k1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005;123(4):569\u201380.","journal-title":"Cell"},{"issue":"21","key":"184_CR57","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","volume":"66","author":"M Zakikhani","year":"2006","unstructured":"Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an amp kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269\u201373.","journal-title":"Cancer Res"},{"issue":"22","key":"184_CR58","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","volume":"67","author":"RJ Dowling","year":"2007","unstructured":"Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804\u201312.","journal-title":"Cancer Res"},{"issue":"20","key":"184_CR59","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","volume":"116","author":"AS Green","year":"2010","unstructured":"Green AS, Chapuis N, Maciel TT, et al. The lkb1\/ampk signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mtor-dependent oncogenic mrna translation. Blood. 2010;116(20):4262\u201373.","journal-title":"Blood"},{"issue":"12","key":"184_CR60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.4161\/cc.20770","volume":"11","author":"J Pan","year":"2012","unstructured":"Pan J, Chen C, Jin Y, et al. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012;11(12):2314\u201326.","journal-title":"Cell Cycle"},{"issue":"13","key":"184_CR61","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1158\/1078-0432.CCR-12-2777","volume":"19","author":"F Morgillo","year":"2013","unstructured":"Morgillo F, Sasso FC, Della Corte CM, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective egfr tyrosine kinase inhibitor, in lkb1 wild-type nsclc cell lines. Clin Cancer Res. 2013;19(13):3508\u201319.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"184_CR62","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1158\/1940-6207.CAPR-10-0055","volume":"3","author":"RM Memmott","year":"2010","unstructured":"Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 2010;3(9):1066\u201376.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"12","key":"184_CR63","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-10-2243","volume":"17","author":"GZ Rocha","year":"2011","unstructured":"Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-induced ampk activation and antitumoral growth. Clin Cancer Res. 2011;17(12):3993\u20134005.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"184_CR64","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4161\/cc.11.2.18813","volume":"11","author":"XS Deng","year":"2012","unstructured":"Deng XS, Wang S, Deng A, et al. Metformin targets stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367\u201376.","journal-title":"Cell Cycle"},{"issue":"4","key":"184_CR65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/1940-6207.CAPR-11-0502","volume":"5","author":"L Vitale-Cross","year":"2012","unstructured":"Vitale-Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila). 2012;5(4):562\u201373.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1\u20132","key":"184_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mce.2014.05.021","volume":"393","author":"SW Cho","year":"2014","unstructured":"Cho SW, Yi KH, Han SK, et al. Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014;393(1\u20132):24\u20139.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"184_CR67","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/1940-6207.CAPR-13-0110","volume":"7","author":"LA Checkley","year":"2014","unstructured":"Checkley LA, Rho O, Angel JM, et al. Metformin inhibits skin tumor promotion in overweight and obese mice. Cancer Prev Res (Phila). 2014;7(1):54\u201364.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"184_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","volume":"6","author":"RJ Shaw","year":"2004","unstructured":"Shaw RJ, Bardeesy N, Manning BD, et al. The lkb1 tumor suppressor negatively regulates mtor signaling. Cancer Cell. 2004;6(1):91\u20139.","journal-title":"Cancer Cell"},{"issue":"3","key":"184_CR69","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/annonc\/mdn758","volume":"20","author":"A Vazquez-Martin","year":"2009","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, et al. The antidiabetic drug metformin: a pharmaceutical ampk activator to overcome breast cancer resistance to her2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol. 2009;20(3):592\u20135.","journal-title":"Ann Oncol"},{"issue":"5","key":"184_CR70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","volume":"115","author":"K Inoki","year":"2003","unstructured":"Inoki K, Zhu T, Guan KL. Tsc2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577\u201390.","journal-title":"Cell"},{"issue":"2","key":"184_CR71","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, et al. Ampk phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214\u201326.","journal-title":"Mol Cell"},{"issue":"9","key":"184_CR72","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/1940-6207.CAPR-10-0178","volume":"3","author":"JA Engelman","year":"2010","unstructured":"Engelman JA, Cantley LC. Chemoprevention meets glucose control. Cancer Prev Res (Phila). 2010;3(9):1049\u201352.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"34","key":"184_CR73","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1200\/JCO.2009.25.3963","volume":"27","author":"RM Memmott","year":"2009","unstructured":"Memmott RM, Dennis PA. Lkb1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol. 2009;27(34):e226 (author reply e227).","journal-title":"J Clin Oncol"},{"issue":"5","key":"184_CR74","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","volume":"11","author":"A Kalender","year":"2010","unstructured":"Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of ampk, inhibits mtorc1 in a rag gtpase-dependent manner. Cell Metab. 2010;11(5):390\u2013401.","journal-title":"Cell Metab"},{"issue":"12","key":"184_CR75","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"184_CR76","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ijc.11487","volume":"107","author":"R Baserga","year":"2003","unstructured":"Baserga R, Peruzzi F, Reiss K. The igf-1 receptor in cancer biology. Int J Cancer. 2003;107(6):873\u20137.","journal-title":"Int J Cancer"},{"issue":"7","key":"184_CR77","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC. Akt\/pkb signaling: navigating downstream. Cell. 2007;129(7):1261\u201374.","journal-title":"Cell"},{"issue":"5600","key":"184_CR78","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by erk, jnk, and p38 protein kinases. Science. 2002;298(5600):1911\u20132.","journal-title":"Science"},{"issue":"4","key":"184_CR79","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1535-6108(02)00055-7","volume":"1","author":"T Lopez","year":"2002","unstructured":"Lopez T, Hanahan D. Elevated levels of igf-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1(4):339\u201353.","journal-title":"Cancer Cell"},{"issue":"11","key":"184_CR80","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.onc.1209955","volume":"26","author":"RA Jones","year":"2007","unstructured":"Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of igf-ir disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007;26(11):1636\u201344.","journal-title":"Oncogene"},{"issue":"21","key":"184_CR81","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-06-0912","volume":"12","author":"AS McCampbell","year":"2006","unstructured":"McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor i receptor and activation of the akt pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12(21):6373\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"184_CR82","doi-asserted-by":"publisher","first-page":"e69001","DOI":"10.1371\/journal.pone.0069001","volume":"8","author":"CF Wang","year":"2013","unstructured":"Wang CF, Zhang G, Zhao LJ, et al. Overexpression of the insulin receptor isoform a promotes endometrial carcinoma cell growth. PLoS ONE. 2013;8(8):e69001.","journal-title":"PLoS ONE"},{"issue":"4","key":"184_CR83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ghir.2007.01.004","volume":"17","author":"DR Clemmons","year":"2007","unstructured":"Clemmons DR, Maile LA, Ling Y, et al. Role of the integrin alphavbeta3 in mediating increased smooth muscle cell responsiveness to igf-i in response to hyperglycemic stress. Growth Horm IGF Res. 2007;17(4):265\u201370.","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"184_CR84","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1210\/en.2013-1925","volume":"155","author":"R Malaguarnera","year":"2014","unstructured":"Malaguarnera R, Sacco A, Morcavallo A, et al. Metformin inhibits androgen-induced igf-ir up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology. 2014;155(4):1207\u201321.","journal-title":"Endocrinology"},{"issue":"1","key":"184_CR85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","volume":"123","author":"M Zakikhani","year":"2010","unstructured":"Zakikhani M, Blouin MJ, Piura E, et al. Metformin and rapamycin have distinct effects on the akt pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010;123(1):271\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"184_CR86","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1210\/me.2009-0474","volume":"24","author":"J Ning","year":"2010","unstructured":"Ning J, Clemmons DR. Amp-activated protein kinase inhibits igf-i signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 s794 and tuberous sclerosis 2 s1345 phosphorylation. Mol Endocrinol. 2010;24(6):1218\u201329.","journal-title":"Mol Endocrinol"},{"key":"184_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/1471-2407-13-235","volume":"13","author":"E Karnevi","year":"2013","unstructured":"Karnevi E, Said K, Andersson R, et al. Metformin-mediated growth inhibition involves suppression of the igf-i receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 2013;13:235.","journal-title":"BMC Cancer"},{"issue":"9","key":"184_CR88","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-09-2229","volume":"16","author":"E Rozengurt","year":"2010","unstructured":"Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin\/insulin-like growth factor-1 receptors and g protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010;16(9):2505\u201311.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"184_CR89","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","volume":"81","author":"JM Kyriakis","year":"2001","unstructured":"Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81(2):807\u201369.","journal-title":"Physiol Rev"},{"issue":"8","key":"184_CR90","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the raf\/mek\/erk pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263\u201384.","journal-title":"Biochim Biophys Acta"},{"issue":"16","key":"184_CR91","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1158\/0008-5472.CAN-06-0809","volume":"66","author":"A Sharma","year":"2006","unstructured":"Sharma A, Tran MA, Liang S, et al. Targeting mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase in the mutant (v600e) b-raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 2006;66(16):8200\u20139.","journal-title":"Cancer Res"},{"issue":"7 Pt 2","key":"184_CR92","doi-asserted-by":"publisher","first-page":"2371s","DOI":"10.1158\/1078-0432.CCR-05-2539","volume":"12","author":"DJ Panka","year":"2006","unstructured":"Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res. 2006;12(7 Pt 2):2371s\u20135s.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"184_CR93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.bcp.2012.12.001","volume":"85","author":"SC Tseng","year":"2013","unstructured":"Tseng SC, Huang YC, Chen HJ, et al. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochem Pharmacol. 2013;85(4):583\u201394.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"184_CR94","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/j.1476-5381.2010.00762.x","volume":"160","author":"YP Hwang","year":"2010","unstructured":"Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced\/extracellular signal-regulated kinase\/activator protein-1. Br J Pharmacol. 2010;160(5):1195\u2013211.","journal-title":"Br J Pharmacol"},{"issue":"13","key":"184_CR95","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.4161\/cc.8.13.8814","volume":"8","author":"B Liu","year":"2009","unstructured":"Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031\u201340.","journal-title":"Cell Cycle"},{"issue":"6","key":"184_CR96","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8(6):909\u201315.","journal-title":"Cell Cycle"},{"issue":"6","key":"184_CR97","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.bbagen.2014.01.023","volume":"1840","author":"BN Zordoky","year":"2014","unstructured":"Zordoky BN, Bark D, Soltys CL, et al. The anti-proliferative effect of metformin in triple-negative mda-mb-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014;1840(6):1943\u201357.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"184_CR98","doi-asserted-by":"publisher","first-page":"e98207","DOI":"10.1371\/journal.pone.0098207","volume":"9","author":"EA Queiroz","year":"2014","unstructured":"Queiroz EA, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, ampk and foxo3a in mcf-7 breast cancer cells. PLoS ONE. 2014;9(5):e98207.","journal-title":"PLoS ONE"},{"issue":"4","key":"184_CR99","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/nnm.11.61","volume":"7","author":"S Monteagudo","year":"2012","unstructured":"Monteagudo S, Perez-Martinez FC, Perez-Carrion MD, et al. Inhibition of p42 mapk using a nonviral vector-delivered sirna potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine (Lond). 2012;7(4):493\u2013506.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"184_CR100","doi-asserted-by":"publisher","first-page":"24.e1","DOI":"10.1016\/j.ajog.2013.03.008","volume":"209","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Celestino J, Schmandt R, et al. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 2013;209(1):24.e1\u201324.e12. doi:\n                    10.1016\/j.ajog.2013.03.008","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"184_CR101","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1751-1097.2012.01165.x","volume":"88","author":"SC Chaudhary","year":"2012","unstructured":"Chaudhary SC, Kurundkar D, Elmets CA, et al. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mtor signaling pathway. Photochem Photobiol. 2012;88(5):1149\u201356.","journal-title":"Photochem Photobiol"},{"issue":"6","key":"184_CR102","doi-asserted-by":"publisher","first-page":"482","DOI":"10.4149\/neo_2011_06_482","volume":"58","author":"N Wu","year":"2011","unstructured":"Wu N, Gu C, Gu H, et al. Metformin induces apoptosis of lung cancer cells through activating jnk\/p38 mapk pathway and gadd153. Neoplasma. 2011;58(6):482\u201390.","journal-title":"Neoplasma"},{"issue":"1","key":"184_CR103","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4161\/cc.8.1.7499","volume":"8","author":"A Vazquez-Martin","year":"2009","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses her2 (erbb-2) oncoprotein overexpression via inhibition of the mtor effector p70s6k1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88\u201396.","journal-title":"Cell Cycle"},{"issue":"2","key":"184_CR104","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-010-0924-x","volume":"126","author":"A Vazquez-Martin","year":"2011","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat. 2011;126(2):355\u201364.","journal-title":"Breast Cancer Res Treat"},{"issue":"49","key":"184_CR105","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/sj.onc.1203221","volume":"18","author":"B Rayet","year":"1999","unstructured":"Rayet B, Gelinas C. Aberrant rel\/nfkb genes and activity in human cancer. Oncogene. 1999;18(49):6938\u201347.","journal-title":"Oncogene"},{"issue":"4","key":"184_CR106","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/7410","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of nf-kappab. Nat Med. 1999;5(4):412\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"184_CR107","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/srao.2001.26034","volume":"11","author":"M Jung","year":"2001","unstructured":"Jung M, Dritschilo A. Nf-kappa b signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol. 2001;11(4):346\u201351.","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"184_CR108","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","volume":"6","author":"BB Aggarwal","year":"2004","unstructured":"Aggarwal BB. Nuclear factor-kappab: the enemy within. Cancer Cell. 2004;6(3):203\u20138.","journal-title":"Cancer Cell"},{"issue":"2","key":"184_CR109","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clon.2006.11.013","volume":"19","author":"RO Escarcega","year":"2007","unstructured":"Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, et al. The transcription factor nuclear factor-kappa b and cancer. Clin Oncol (R Coll Radiol). 2007;19(2):154\u201361.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"19","key":"184_CR110","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1158\/1078-0432.CCR-13-0203","volume":"19","author":"L Zheng","year":"2013","unstructured":"Zheng L, Yang W, Wu F, et al. Prognostic significance of ampk activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19(19):5372\u201380.","journal-title":"Clin Cancer Res"},{"issue":"6859","key":"184_CR111","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105\u201311.","journal-title":"Nature"},{"key":"184_CR112","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","volume":"58","author":"P Dalerba","year":"2007","unstructured":"Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267\u201384.","journal-title":"Annu Rev Med"},{"issue":"9","key":"184_CR113","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/sj.onc.1210200","volume":"26","author":"H Lou","year":"2007","unstructured":"Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and abc transporters. Oncogene. 2007;26(9):1357\u201360.","journal-title":"Oncogene"},{"issue":"12","key":"184_CR114","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"27","author":"S Ma","year":"2008","unstructured":"Ma S, Lee TK, Zheng BJ, et al. Cd133+\u00a0hcc cancer stem cells confer chemoresistance by preferential expression of the akt\/pkb survival pathway. Oncogene. 2008;27(12):1749\u201358.","journal-title":"Oncogene"},{"issue":"10","key":"184_CR115","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrd2137","volume":"8","author":"BB Zhou","year":"2009","unstructured":"Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8(10):806\u201323.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"184_CR116","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1541-7786.MCR-09-0030","volume":"7","author":"G Frosina","year":"2009","unstructured":"Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res. 2009;7(7):989\u201399.","journal-title":"Mol Cancer Res"},{"issue":"7120","key":"184_CR117","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756\u201360.","journal-title":"Nature"},{"issue":"24","key":"184_CR118","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/jnci\/djj495","volume":"98","author":"TM Phillips","year":"2006","unstructured":"Phillips TM, McBride WH, Pajonk F. The response of cd24(-\/low)\/cd44+\u00a0breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777\u201385.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"184_CR119","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nrc2419","volume":"8","author":"M Baumann","year":"2008","unstructured":"Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8(7):545\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"184_CR120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4161\/cc.8.1.7533","volume":"8","author":"AB Alvero","year":"2009","unstructured":"Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8(1):158\u201366.","journal-title":"Cell Cycle"},{"issue":"19","key":"184_CR121","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507\u201311.","journal-title":"Cancer Res"},{"issue":"9","key":"184_CR122","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","volume":"71","author":"D Iliopoulos","year":"2011","unstructured":"Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71(9):3196\u2013201.","journal-title":"Cancer Res"},{"issue":"3","key":"184_CR123","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1940-6207.CAPR-11-0299","volume":"5","author":"B Bao","year":"2012","unstructured":"Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating csc function mediated by deregulating mirnas in pancreatic cancer cells. Cancer Prev Res (Phila). 2012;5(3):355\u201364.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"184_CR124","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1593\/tlo.13556","volume":"6","author":"A Mohammed","year":"2013","unstructured":"Mohammed A, Janakiram NB, Brewer M, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mtor signaling. Transl Oncol. 2013;6(6):649\u201359.","journal-title":"Transl Oncol"},{"issue":"2","key":"184_CR125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ijo.2014.2450","volume":"45","author":"S Honjo","year":"2014","unstructured":"Honjo S, Ajani JA, Scott AW, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mtor pathway in esophageal cancer. Int J Oncol. 2014;45(2):567\u201374.","journal-title":"Int J Oncol"},{"issue":"1","key":"184_CR126","first-page":"135","volume":"25","author":"A Vazquez-Martin","year":"2011","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein cd24 in mda-mb-468 triple-negative breast cancer cells. Oncol Rep. 2011;25(1):135\u201340.","journal-title":"Oncol Rep"},{"key":"184_CR127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/srep00362","volume":"2","author":"CW Song","year":"2012","unstructured":"Song CW, Lee H, Dings RP, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2:362.","journal-title":"Sci Rep"},{"issue":"3","key":"184_CR128","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1073\/pnas.1221055110","volume":"110","author":"HA Hirsch","year":"2013","unstructured":"Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA. 2013;110(3):972\u20137.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Chinese Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-017-0184-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T17:03:25Z","timestamp":1526144605000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancercommun.biomedcentral.com\/articles\/10.1186\/s40880-017-0184-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,26]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1186\/s40880-017-0184-9","relation":{},"ISSN":["1944-446X"],"issn-type":[{"value":"1944-446X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,26]]},"article-number":"17"}}